{"id":{"repo_id":"ajou","oai_identifier":"oai:repository.ajou.ac.kr:201003/7593"},"canonical_url":"https://search.dev.ndltd.org/etd/ajou/oai:repository.ajou.ac.kr:201003/7593","repository":{"repo_id":"ajou","name":"Ajou University","base_url":"http://repository.ajou.ac.kr/oai/request"},"display":{"title":"Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis","abstract":"Background: Add on adefovir (ADV) to ongoing lamivudine (LAM) is an established treatment modality for treatment of LAM resistance with chronic hepatitis B. We assessed the long?term efficacy (median follow-up of 20.18 months) of ADV add-on LAM therapy in 89 LAM-resistant patients. Methods: 89 patients (29.2% cirrhotics, 76.4% hepatitis B e antigen positive) with LAM resistant patients who were not experienced ADV monotherapy were enrolled, retrospectively from August 2005 to October 2010. All the patients were treated with ADV add-on LAM therapy. Liver function test, hepatitis B virus (HBV) DNA and HBeAg/HBeAb were assessed every 3 months. ADV associated (rtA181T/V and rtN236T) mutations were looked for at intervals in all HBV DNA-positive serum samples, yearly Results: Cumulative ratio of undetectable HBV DNA level (<50 copies/mL or <8.6 IU/mL) at 6 months, 1 year, and 2 years were 15.7%/44.2%/45.4% for HBeAg positive group and 34.8%/39.1%/52.6% in HBeAg negative group. Seroconversion was observed 10.2%/19.7%/23.6% in 6 months, 1 year, and 2 years. Virologic breakthrough phenomenon was seen 1.1%. Conclusions: LAM and ADV combination therapy effectively suppresses HBV replication and prevents virologic and clinical breakthrough in LMV-resistant patients. And emergence of ADV-resistant mutants is rare, at least over a period of 24 months.","abstract_html":"Background: Add on adefovir (ADV) to ongoing lamivudine (LAM) is an established treatment modality for treatment of LAM resistance with chronic hepatitis B. We assessed the long?term efficacy (median follow-up of 20.18 months) of ADV add-on LAM therapy in 89 LAM-resistant patients. Methods: 89 patients (29.2% cirrhotics, 76.4% hepatitis B e antigen positive) with LAM resistant patients who were not experienced ADV monotherapy were enrolled, retrospectively from August 2005 to October 2010. All the patients were treated with ADV add-on LAM therapy. Liver function test, hepatitis B virus (HBV) DNA and HBeAg/HBeAb were assessed every 3 months. ADV associated (rtA181T/V and rtN236T) mutations were looked for at intervals in all HBV DNA-positive serum samples, yearly Results: Cumulative ratio of undetectable HBV DNA level (&lt;50 copies/mL or &lt;8.6 IU/mL) at 6 months, 1 year, and 2 years were 15.7%/44.2%/45.4% for HBeAg positive group and 34.8%/39.1%/52.6% in HBeAg negative group. Seroconversion was observed 10.2%/19.7%/23.6% in 6 months, 1 year, and 2 years. Virologic breakthrough phenomenon was seen 1.1%. Conclusions: LAM and ADV combination therapy effectively suppresses HBV replication and prevents virologic and clinical breakthrough in LMV-resistant patients. And emergence of ADV-resistant mutants is rare, at least over a period of 24 months.","abstract_has_math":false,"creators":["김, 동훈"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["조, 성원","대학원 의학과","201024229"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2012,"date_issued":"2012-10-31T04:18:09Z","date_published":"2012-10-31T04:18:09Z","updated_at":"2026-07-24T00:51:39Z","subjects":["만성 B형 간염","라미부딘 내성","아데포비어","바이러스 돌파"],"languages":["ko"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000012181","000000012181"],"render_values":[{"text":"http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000012181","href":"http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000012181","code":true},{"text":"000000012181","href":null,"code":true}]}]},"links":{"outbound_url":"http://repository.ajou.ac.kr/handle/201003/7593","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["조, 성원","대학원 의학과","201024229","김, 동훈"]},{"key":"dc:creator","label":"Author","values":["김, 동훈"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2012-10-31T04:18:09Z","2012"]},{"key":"dc:type","label":"Dc Type","values":["Thesis","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["만성 B형 간염","라미부딘 내성","아데포비어","바이러스 돌파"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["ko"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://repository.ajou.ac.kr/handle/201003/7593","http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000012181","000000012181"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Background: Add on adefovir (ADV) to ongoing lamivudine (LAM) is an established treatment modality for treatment of LAM resistance with chronic hepatitis B. We assessed the long?term efficacy (median follow-up of 20.18 months) of ADV add-on LAM therapy in 89 LAM-resistant patients. Methods: 89 patients (29.2% cirrhotics, 76.4% hepatitis B e antigen positive) with LAM resistant patients who were not experienced ADV monotherapy were enrolled, retrospectively from August 2005 to October 2010. All the patients were treated with ADV add-on LAM therapy. Liver function test, hepatitis B virus (HBV) DNA and HBeAg/HBeAb were assessed every 3 months. ADV associated (rtA181T/V and rtN236T) mutations were looked for at intervals in all HBV DNA-positive serum samples, yearly Results: Cumulative ratio of undetectable HBV DNA level (<50 copies/mL or <8.6 IU/mL) at 6 months, 1 year, and 2 years were 15.7%/44.2%/45.4% for HBeAg positive group and 34.8%/39.1%/52.6% in HBeAg negative group. Seroconversion was observed 10.2%/19.7%/23.6% in 6 months, 1 year, and 2 years. Virologic breakthrough phenomenon was seen 1.1%. Conclusions: LAM and ADV combination therapy effectively suppresses HBV replication and prevents virologic and clinical breakthrough in LMV-resistant patients. And emergence of ADV-resistant mutants is rare, at least over a period of 24 months.","국문요약 차례 그림 차례 표 차례 Ⅰ. 서론 1 Ⅱ. 연구대상 및 방법 3 A. 연구대상 3 B. 연구방법 3 C. 통계 4 Ⅲ. 결과 5 A. 대상 환자군의 치료 전 특성 5 B. 치료 반응 6 C. 바이러스 돌파 현상의 관찰 9 D. 유전자형 내성 빈도의 관찰 10 Ⅳ. 고찰 14 Ⅴ. 결론 17 참고문헌 18 ABSTRACT 22","Master"]},{"key":"dc:title","label":"Title","values":["Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis","라미부딘 내성 만성 B형 간염 환자에 있어 라미부딘과 아데포비어 병용 요법의 치료 효과와 특성 분석"]}]}],"canonical_facts":{"dc:contributor":["조, 성원","대학원 의학과","201024229","김, 동훈"],"dc:creator":["김, 동훈"],"dc:date":["2012-10-31T04:18:09Z","2012"],"dc:description":["Background: Add on adefovir (ADV) to ongoing lamivudine (LAM) is an established treatment modality for treatment of LAM resistance with chronic hepatitis B. We assessed the long?term efficacy (median follow-up of 20.18 months) of ADV add-on LAM therapy in 89 LAM-resistant patients. Methods: 89 patients (29.2% cirrhotics, 76.4% hepatitis B e antigen positive) with LAM resistant patients who were not experienced ADV monotherapy were enrolled, retrospectively from August 2005 to October 2010. All the patients were treated with ADV add-on LAM therapy. Liver function test, hepatitis B virus (HBV) DNA and HBeAg/HBeAb were assessed every 3 months. ADV associated (rtA181T/V and rtN236T) mutations were looked for at intervals in all HBV DNA-positive serum samples, yearly Results: Cumulative ratio of undetectable HBV DNA level (<50 copies/mL or <8.6 IU/mL) at 6 months, 1 year, and 2 years were 15.7%/44.2%/45.4% for HBeAg positive group and 34.8%/39.1%/52.6% in HBeAg negative group. Seroconversion was observed 10.2%/19.7%/23.6% in 6 months, 1 year, and 2 years. Virologic breakthrough phenomenon was seen 1.1%. Conclusions: LAM and ADV combination therapy effectively suppresses HBV replication and prevents virologic and clinical breakthrough in LMV-resistant patients. And emergence of ADV-resistant mutants is rare, at least over a period of 24 months.","국문요약 차례 그림 차례 표 차례 Ⅰ. 서론 1 Ⅱ. 연구대상 및 방법 3 A. 연구대상 3 B. 연구방법 3 C. 통계 4 Ⅲ. 결과 5 A. 대상 환자군의 치료 전 특성 5 B. 치료 반응 6 C. 바이러스 돌파 현상의 관찰 9 D. 유전자형 내성 빈도의 관찰 10 Ⅳ. 고찰 14 Ⅴ. 결론 17 참고문헌 18 ABSTRACT 22","Master"],"dc:identifier":["http://repository.ajou.ac.kr/handle/201003/7593","http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000012181","000000012181"],"dc:language":["ko"],"dc:subject":["만성 B형 간염","라미부딘 내성","아데포비어","바이러스 돌파"],"dc:title":["Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis","라미부딘 내성 만성 B형 간염 환자에 있어 라미부딘과 아데포비어 병용 요법의 치료 효과와 특성 분석"],"dc:type":["Thesis","Theses"]},"updated_at":"2026-07-24T00:51:39Z"}